BioPharma Dive March 28, 2025
The new bid surpasses an offer SK Capital and Carlyle Group made last month for the pioneering gene therapy developer, which Bluebird’s board still supports.
Bluebird bio on Friday received a new buyout offer that surpasses a take-private bid the pioneering gene therapy developer received last month.
In a short statement, Bluebird confirmed Ayrmid Ltd., the parent company of cell therapy developer Gamida Cell, has offered to buy the company in a deal valuing it at about $45 million. Through that deal, Ayrmid would acquire Bluebird for $4.50 per share upfront as well as a so-called contingent value right that would give its stockholders another $6.84 per share if an unspecified sales milestone is met.
The deal values Bluebird at...
Today's Sponsors
Today's Sponsor